Cidara Therapeutics Inc Stock
-
Your prediction
Cidara Therapeutics Inc Stock
Pros and Cons of Cidara Therapeutics Inc in the next few years
Pros
Cons
Performance of Cidara Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cidara Therapeutics Inc | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -0.760% | -1.515% | -2.985% | -15.033% | -21.687% | -53.982% | -81.944% |
| Celldex Therapeutics | 2.590% | 1.020% | -9.174% | -9.174% | -10.000% | -50.276% | -10.891% |
| Achieve Life Sciences Inc. | 4.300% | 6.277% | -25.333% | 20.530% | -1.622% | -28.205% | -67.207% |
Comments
News
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
According to a November 14, 2025 SEC filing, HighVista Strategies LLC initiated a new stake in Cidara Therapeutics (NASDAQ:CDTX), acquiring 70,904 shares worth $6.79 million as of September 30
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
Just prior to last week's takeover news, Cidara Therapeutics (NASDAQ: CDTX) was already one of the year's top-performing stocks. Trading in the mid-$20s at the start of 2025, by mid-November, this



